MacroGenics (MGNX) to Release Quarterly Earnings on Tuesday

Posted by George Bondi on May 5th, 2026

MacroGenics (NASDAQ:MGNX – Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect MacroGenics to post earnings of ($0.56) per share and revenue of $16.29 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

MacroGenics (NASDAQ:MGNX – Get Free Report) last posted its quarterly earnings data on Monday, March 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.20. MacroGenics had a negative net margin of 49.91% and a negative return on equity of 120.19%. The firm had revenue of $41.23 million for the quarter, compared to the consensus estimate of $27.81 million. On average, analysts expect MacroGenics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

MacroGenics Trading Down 2.0%

NASDAQ MGNX traded down $0.07 during trading hours on Tuesday, reaching $3.14. 159,921 shares of the company traded hands, compared to its average volume of 996,487. MacroGenics has a 12 month low of $1.18 and a 12 month high of $3.88. The stock has a market capitalization of $199.26 million, a PE ratio of -2.68 and a beta of 1.08. The company has a 50 day moving average of $2.89 and a two-hundred day moving average of $2.07.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Invesco Ltd. lifted its position in shares of MacroGenics by 31.6% in the 4th quarter. Invesco Ltd. now owns 111,121 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 26,668 shares during the last quarter. Mackenzie Financial Corp bought a new position in shares of MacroGenics in the 4th quarter worth about $324,000. XTX Topco Ltd lifted its position in shares of MacroGenics by 38.2% in the 4th quarter. XTX Topco Ltd now owns 240,327 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 66,368 shares during the last quarter. Quadrature Capital Ltd lifted its position in shares of MacroGenics by 521.5% in the 4th quarter. Quadrature Capital Ltd now owns 265,465 shares of the biopharmaceutical company’s stock worth $427,000 after buying an additional 222,751 shares during the last quarter. Finally, Amundi bought a new position in shares of MacroGenics in the 4th quarter worth about $345,000. 96.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on MGNX. Wall Street Zen upgraded shares of MacroGenics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Barclays increased their price objective on shares of MacroGenics from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Monday, April 20th. B. Riley Financial upgraded shares of MacroGenics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $3.00 to $9.00 in a research note on Friday, April 10th. Finally, Citigroup reiterated a “market perform” rating on shares of MacroGenics in a research note on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $5.40.

Get Our Latest Analysis on MGNX

MacroGenics Company Profile

(Get Free Report)

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.